Dendreon CEO Johnson Resigns as Provenge Overtaken by Rivals
This article is for subscribers only.
Dendreon Corp.’s Chief Executive Officer John H. Johnson plans to resign this summer for personal reasons, as sales of the company’s prostate-cancer drug Provenge stagnate.
Johnson resigned as chairman of the board effective June 3, and was replaced by Douglas G. Watson, previously the independent director. The New Brunswick, New Jersey-based drugmaker is looking for a successor to Johnson, who plans to depart on August 15, the company said in a statement today.